Topics

PubMed Journals Articles About "Drug Decreases Leakiness Associated With Ulcerative Colitis" RSS

19:55 EST 27th January 2020 | BioPortfolio

Drug Decreases Leakiness Associated With Ulcerative Colitis PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Drug Decreases Leakiness Associated With Ulcerative Colitis articles that have been published worldwide.

More Information about "Drug Decreases Leakiness Associated With Ulcerative Colitis" on BioPortfolio

We have published hundreds of Drug Decreases Leakiness Associated With Ulcerative Colitis news stories on BioPortfolio along with dozens of Drug Decreases Leakiness Associated With Ulcerative Colitis Clinical Trials and PubMed Articles about Drug Decreases Leakiness Associated With Ulcerative Colitis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Drug Decreases Leakiness Associated With Ulcerative Colitis Companies in our database. You can also find out about relevant Drug Decreases Leakiness Associated With Ulcerative Colitis Drugs and Medications on this site too.

Showing "Drug decreases leakiness associated with ulcerative colitis" PubMed Articles 1–25 of 11,000+

Tacrolimus for ulcerative colitis in children: a multicenter survey in Japan.

Tacrolimus is effective for refractory ulcerative colitis in adults, while data for children is sparse. We aimed to evaluate the effectiveness and safety of tacrolimus for induction and maintenance therapy in Japanese children with ulcerative colitis.


Healthy Eating Index-2015 as a Predictor of Ulcerative Colitis Risk in a Case-Control Cohort.

There is substantial compelling clinical evidence implicating certain dietary components in the development and clinical course of progression in ulcerative colitis (UC). The current study aimed to assess whether there exists any association between ulcerative colitis and scores on a healthy eating index.

Systemic molecular mediators of inflammation differentiate between Crohn's disease and ulcerative colitis, implicating threshold levels of IL-10 and relative ratios of pro-inflammatory cytokines in therapy.

Faecal diversion is associated with improvements in Crohn's disease but not ulcerative colitis, indicating differing mechanisms mediate the diseases. This study aimed to investigate levels of systemic mediators of inflammation, including fibrocytes and cytokines, in (1) in patients with Crohn's disease and ulcerative colitis pre-operatively and compare with healthy controls and (2) in patients with Crohn's disease and ulcerative colitis prior to and following faecal diversion.


Identification of the most cost effective position of vedolizumab among the available biologic drugs for the treatment of ulcerative colitis.

There are limited data on the most cost-effective sequencing of biologics for ulcerative colitis (UC).

Prospective cohort study of appendicectomy for treatment of therapy-refractory ulcerative colitis.

Appendicectomy may reduce relapses and need for medication in patients with ulcerative colitis, but long-term prospective data are lacking. This study aimed to analyse the effect of appendicectomy in patients with refractory ulcerative colitis.

Honey Polyphenols Ameliorate DSS-induced Ulcerative Colitis Via Modulating Gut Microbiota in Rats.

Ulcerative colitis (UC) is a multifaceted and recurrent immune disorder that requires long-term potent pharmacological treatment. Honey, as a natural food of nourishment and pharmaceutical value, has been found to defend against colitis.

Resolution of ulcerative colitis.

Ulcerative colitis designates an idiopathic chronic inflammatory bowel disease leading to bloody diarrhea and inflammatory alterations mostly restricted to the large intestine. Many studies continue to unravel important aspects of its etiopathogenesis, and recent pharmaceutical developments broaden the arsenal of therapeutic opportunity. In this review, we delve into the cellular and molecular determinants of successful resolution of ulcerative colitis, describing novel insights in each of the phases of muc...

The TLR9 agonist cobitolimod induces IL10 producing wound healing macrophages and regulatory T cells in ulcerative colitis.

The topically applied Toll-like receptor 9 (TLR9) agonist cobitolimod is a first-in-class DNA-based oligonucleotide that demonstrated therapeutic efficacy in clinical trials with ulcerative colitis (UC) patients. We here characterized its anti-inflammatory mechanism in UC.

The Ulcerative Colitis Response Index for Detection of Mucosal Healing in Patients Treated With Anti-tumour Necrosis Factor.

Surrogate markers that accurately detect mucosal healing [MH] in patients with ulcerative colitis [UC] are urgently needed. Several stool neutrophil-related proteins are currently used as biomarkers for MH. However, the sensitivity and specificity are not sufficient to avoid unnecessary endoscopic evaluations.

Infliximab clinically treating ulcerative colitis: A systematic review and meta-analysis.

This review aimed to evaluate the efficacy and safety of infliximab against ulcerative colitis (UC).

Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis.

Golimumab is a new anti-TNF-alpha monoclonal antibody for patients with ulcerative colitis.

Oral Nano Vitamin D Supplementation Reduces Disease Activity in Ulcerative Colitis: A Double-Blind Randomized Parallel Group Placebo-controlled Trial.

Vitamin D possesses anti-inflammatory properties and could be beneficial in ulcerative colitis (UC).

Systematic review: Clinical utility of gastrointestinal ultrasound in the diagnosis, assessment and management of patients with ulcerative colitis.

Gastrointestinal ultrasound is useful in the assessment of patients with Crohn's disease, but its application in ulcerative colitis is less well established.

Prognostic significance of faecal eosinophil granule proteins in inflammatory bowel disease.

Non-invasive markers for predicting relapse would be a useful tool for the management of patients with inflammatory bowel disease. Eosinophil granulocytes and their granule proteins eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EDN) have previously been shown to reflect disease activity in Crohn's disease and ulcerative colitis. To examine the capacity of faecal ECP and EDN to predict relapse in ulcerative colitis and Crohn's disease, and to compare these proteins with faecal calprot...

Targeting Immune Cell Wiring in Ulcerative Colitis.

The cytokine TNF is thought to play a major role in the immunopathogenesis of ulcerative colitis, and anti-TNF antibodies are considered as cornerstones of clinical therapy. Two clinical trials published in The New England Journal of Medicine now challenge this paradigm and suggest new avenues for research.

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.

Biologic therapies are widely used in patients with ulcerative colitis. Head-to-head trials of these therapies in patients with inflammatory bowel disease are lacking.

Aqueous extract of Bruguiera gymnorrhiza leaves protects against dextran sulfate sodium induced ulcerative colitis in mice via suppressing NF-κB activation and modulating intestinal microbiota.

Ulcerative colitis (UC) is tightly associated with inflammation response and oxidative stress. As a folk medicine applied in treatment of diarrhea, Bruguiera gymnorrhiza also possesses anti-inflammatory and anti-oxidative activities, which indicated that B. gymnorrhiza may exert anti-colitis effect.

Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis.

New oral therapeutic agents are needed for patients with ulcerative colitis (UC) who are unresponsive or intolerant to conventional therapy.

Faecal Calprotectin Predicts Endoscopic and Histological Activity in Clinically Quiescent Ulcerative Colitis.

Faecal calprotectin [FC] is a reliable surrogate marker for disease activity in ulcerative colitis [UC]; however, there are no consensus cut-off values for remission. The study aim was to correlate FC with Mayo Endoscopic Score [MES] and histological disease activity of UC patients in clinical remission.

Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis: Ustekinumab PK and exposure-response in UC.

The efficacy of antibody-based therapeutics depends on their pharmacokinetics. The pharmacokinetic and exposure response profiles of ustekinumab, a monoclonal antibody against interleukin 12/interleukin 23, are known in patients with Crohn's disease, yet there are few data from patients with ulcerative colitis. We characterized ustekinumab's pharmacokinetics, exposure response, and optimal serum concentrations in patients with ulcerative colitis.

Cannabis for the Treatment of Crohn's Disease and Ulcerative Colitis: Evidence From Cochrane Reviews.

We systematically reviewed the safety and effectiveness of cannabis and cannabinoids treatment for Crohn's disease (CD) and ulcerative colitis (UC).

Colonic Mucosa associated Candida as assessed by biopsy culture is associated with disease severity in ulcerative colitis: A prospective study.

To know the relationship of Mucosa Associated Candida(MAC) and disease severity in patients with Ulcerative Colitis (UC).

Elevated Colonic Mucin Expression Correlates with Extended Time to Surgery for Ulcerative Colitis Patients.

Both genetic and environmental factors contribute to the development and persistence of ulcerative colitis (UC). As supported by differential responses to therapy, multiple subclasses of disease likely comprise UC. We reasoned that profiling the colonic transcriptomes may offer one approach to molecular subtype UC.

True cytomegalovirus colitis is a poor prognostic indicator in patients with ulcerative colitis flares: the 10-year experience of an academic referral inflammatory bowel disease center.

The impact of cytomegalovirus (CMV) colitis on long-term outcomes of ulcerative colitis (UC) flares remains controversial. A total of 257 UC patients with moderate-to-severe flares were observed for a mean follow-up of 41.2 months. CMV colitis was defined as histopathologic confirmation of CMV inclusions obtained from macroscopic endoscopic lesions in patients with UC flares. An independent gastrointestinal pathologist prospectively reviewed all specimens. A poor outcome was defined as any of hospitalizati...

Role of Fecal Calprotectin as a Noninvasive Indicator for Ulcerative Colitis Disease Activity.

It is essential in clinical management to determine the disease activity in ulcerative colitis (UC) patients. At present, the most accurate way of evaluating the UC severity is endoscopy with biopsy. Fecal calprotectin (FCP) is a non-invasive biomarker that is frequently used for monitoring of intestinal inflammation.


Quick Search